Monitor the Commission's final determination on remedy, expected after the November 6, 2026 reply deadline. If exclusion orders are issued, Seer's competitive position could strengthen, but the impact depends on the scope of the orders and the materiality of Nanomics' products to Seer's business.
Price Chart
Executive Summary
The USITC has found the sole respondent, Nanomics Biotechnology Co., Ltd., in default in Investigation No. 337-TA-1508, which concerns patents held by Seer, Inc. related to protein study systems and supplies. The Commission is now seeking submissions on remedy, public interest, and bonding, which could lead to exclusion and cease-and-desist orders against Nanomics' products. This is a procedural step toward a potential remedy, but no final orders have been issued yet.
ITC Section 337 Details
Key Facts
- The Commission determined not to review the initial default finding against Nanomics Biotechnology Co., Ltd.
- The investigation involves five U.S. patents (11,435,360; 11,630,112; 12,050,222; 12,228,566; 12,590,948) owned by Seer, Inc. and The Brigham and Women's Hospital.
- Written submissions on remedy, public interest, and bonding are due by October 30, 2026, with replies by November 6, 2026.
- No final exclusion or cease-and-desist orders have been issued; the Commission is still considering the appropriate remedy.
Financial Impact
Not quantifiable from the filing; no remedy has been ordered yet.
Risk Factors
- The Commission may decide not to issue exclusion orders or may limit their scope.
- Any remedy is subject to a 60-day Presidential review period, during which imports could continue under bond.
- Nanomics may appeal any final determination to the Federal Circuit.
Investment Themes
Documents Analyzed
This report is based on 1 USITC notice.
| Document | Accession Number |
|---|---|
| ITC-337 Data (Synthetic) | itc-2026-21100-SEER |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $1.97 | awaiting T+20 | — | $1.99 (+1.02%) |
Oct 15, 2026 12d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.99 (−1.97%) |
Oct 8, 2026 18d ago | 3 | $2.19 | awaiting T+20 | — | $1.99 (−9.13%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.99 (+6.99%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.99 (−10.36%) |
Jul 28, 2026 12w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.99 (+4.33%) |
Jul 28, 2026 13w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.99 (−7.01%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.99 (−2.45%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.99 (−2.45%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.99 (−8.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time ITC Section 337 Intelligence
Market-moving USITC Section 337 notices analyzed within minutes. Complaints, exclusion orders, final determinations, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers